TEAM-Trial: Targeting Epigenetic Therapy Resistance in AML With Bortezomib

• Status: Recruiting
• Trial end date: 2021-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The long-term outcome of patients with acute myeloid leukemia (AML) remains poor, with less than 30% of patients achieving long lasting remission or cure. This poor outcome is largely due to refractoriness to induction chemotherapy as well as relapses during and after completion of intensive induction and consolidation therapy. In patients with refractory/relapsed AML hematopoietic cell transplantation (allo-HCT) is currently the only treatment option offering a prospect of cure but outcome is heavy influenced by the remission status before allo-HCT. Therefore, patients are typically treated with salvage regimens based on high dose cytarabine (HiDAC) combined with mitoxantrone, fludarabine or idarubicin. Nevertheless, the remission rates remain poor and currently there is no accepted standard salvage regimen. Recent studies indicate that combination chemotherapy including HiDAC and gemtuzumab ozogamicin (GO) at a dose of 3 mg/m² leads to improved response rates in refractory AML.

Proteasome inhibition with bortezomib appears to be a promising treatment strategy to restore chemo-sensitivity via EZH2 stabilisation.

This study aims at improving response rates in refractory/ relapsed AML by combining high dose cytarabine, gemtuzumab ozogamicin (GA) and bortezomib (B).

During this phase II study efficacy of B-GA is assessed in comparison to matched historical controls using the Matched Threshold Crossing (MTC)-approach. If results are promising, a subsequent randomized phase III study is intended to assess the efficacy of GA with or without bortezomib.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University Hospital Heidelberg
• Collaborator: National Center for Tumor Diseases, Heidelberg
• Treatments: Bortezomib; Gemtuzumab

Criteria

Inclusion Criteria:

• Patients with confirmed diagnosis of AML according to WHO-2016 [27] (except acute promyelocytic leukemia) either de novo AML, AML after preceding myelodysplastic or myeloproliferative syndrome (MDS/MPD), and therapy related AML (t-AML) after previous cytotoxic therapy or radiation are eligible either refractory (A) to first line chemotherapy or in first relapse (B), also after stem cell transplantation. FLT3-ITD status, cytogenetics (refractory and relapsed patients), in addition status of core-binding-factor as well as double mutant CEBPA in relapsed patients must be available.

A) Refractory to induction therapy is defined as no CR, CRi (according to standard criteria) [4] after 2 intensive induction cycles of at least 7 days of cytarabine 100-200 mg/m² continuously or an equivalent regimen with cytarabine with total dose not less than 700 mg/m² per cycle and 3 days of an anthracycline/ anthraquinone (e.g. daunorubicin, idarubicin).

B) Relapsed after first line therapy is defined as relapsed AML after CR or CRi (according to standard criteria) after at least one intensive induction and consolidation (including intensive chemotherapy and/or hematopoietic cell transplantation) therapy.

• ECOG performance status ≤ 2

• Discontinuation of prior AML treatment before the start of study treatment (except hydroxyurea or other treatment to control hyperleukocytosis) for at least 10 days for cytotoxic agents and 5 half-lives for non-cytotoxic/ investigational drug treatment preceding the first dose of trial medications

• Age ≥ 18 years

• Pregnancy and childbearing potential:

• Non-pregnant and non-nursing women of childbearing potential must have a negative serum or urine ß-HCG pregnancy test within a sensitivity of at least 25 mIU/mL within 72 hours prior to registration ("Women of childbearing potential" is defined as a sexually active mature woman who has not undergone a hysterectomy or who has had menses at any time in the preceding 24 consecutive months).

• Female patients of reproductive age must agree to avoid getting pregnant while on therapy.

• Women of child-bearing potential must either commit to continued abstinence from heterosexual intercourse or begin highly effective methods of birth control during study and for at least 7 months after end of treatment.

• Men must use a latex condom during any sexual contact with women of childbearing potential, even if they have undergone a successful vasectomy and must agree to avoid to father a child during study and until 6 months after end of study/treatment.

• Willingness of patient to adhere to protocol specific requirements and capacity to give written informed consent

• Ability of patient to understand the character and individual consequences of clinical Trial

• Following receipt of verbal and written information about the study, the patient must provide signed informed consent before any study related activity is carried out

Exclusion Criteria:

• Acute promyelocytic leukemia (AML M3)

• Acute myeloid leukemia previously treated with gemtuzumab ozogamicin

• Hyperleukocytosis (leukocytes > 30,000/μl) at the time of study entry. These patients should be treated with hydroxyurea and / or receive leukocytapheresis treatment according to routine practice and are only allowed to enter into the study when leukocyte counts of 30,000/μl or below are reached. If hydroxyurea is not sufficient to control hyperleukocytosis i.v. application of 100 mg cytarabine continuously over 24 hours may be discussed with the coordinating investigator or the scientific coordinator

• Known central nervous system manifestation of AML

• uncontrolled or significant cardiovascular disease, including any of the following:

• History of heart failure NYHA class 3 or 4

• Left ventricular ejection fraction (LVEF) ≤ 40% by echocardiogram

• History of uncontrolled angina pectoris or myocardial infarction within 12 months prior to screening

• History of second (Mobitz II) or third degree heart block or any cardiac arrhythmias requiring anti-arrhythmic therapy (beta blockers or digoxin are permitted)

• Pregnant or nursing woman

• Chronically impaired renal function (creatinine clearance < 30 ml / min)

• Inadequate liver function (ALT and AST ≥ 2 x ULN), total bilirubin ≥ 1.5 x ULN

• Known liver cirrhosis or history of veno-occlusive disease (VOD)

• HIV infection and/or active hepatitis B or C infection (active hepatitis B defined by HBs Ag positivity, active hepatitis C defined by positive virus load)

• Evidence or history of severe non-leukemia associated bleeding diathesis or coagulopathy

• Uncontrolled active infection

• Concurrent malignancies other than AML with an estimated life expectancy of less than two years

• Known hypersensitivity to cytarabine (AraC) (not including drug fever, conjunctivitis or exanthema)

• Known hypersensitivity to bortezomib, boron or mannitol

• Isolated extramedullary manifestation of AML

• Patients within 100 days after allogeneic stem cell transplantation at the time of Screening

• Patients with clinically relevant Graft-versus-Host-Disease (GvHD) requiring initiation of treatment or treatment escalation within 21 days prior to Screening

• Patients with pre-existing severe neuropathy

• Acute diffuse infiltrative pulmonary disease

• Pericardial disease

• Expected incompliance of patient